Seventy-six per cent of biotech, medtech and health tech companies surveyed reveal they will be worse off under R&D Tax Incentive changes
AusBiotech
11 June 2026
More than three quarters of Australia’s biotech, medtech and health tech companies recently surveyed said they will be significantly or moderately negatively impacted by the proposed Budget changes to the R&D Tax Incentive (RDTI), with many actively considering relocating overseas, or moving lifesaving clinical trials, due to the controversial reforms.
The proposal to limit the RDTI’s long standing refundable tax offset for companies less than 10 years old is not fit-for-purpose and does not cater to the realities of the sector.
The development of a new medicine, vaccine or advanced therapeutic routinely takes well in excess of a decade. Companies in this sector spend years developing new medical products that improve and save lives in Australia and around the world.
Australian health and medical companies navigate multiple commercial 'valleys of death' as they progress from research through pre-clinical development, clinical trials, regulatory approval and manufacturing scale-up before revenue generation through market access is even possible.
For Australian biotech, medtech and health tech companies, the long standing refundable RDTI is a vital source of cashflow that supports Australian R&D, investment, skilled jobs, and retention of businesses and intellectual property.
Industry peak body AusBiotech recently conducted a nationwide survey with its members, canvassing views on the proposed changes and its likely impacts.
Key insights from the survey include:
- Fifty-nine companies responded, with 76% indicating they will be either significantly or moderately impacted.
- Of these, 30 said the changes would impact them significantly, which could involve moving overseas to more favourable countries, moving critical clinical trials overseas or reconsidering Australian manufacturing.
- One hundred per cent of companies aged 6 – 15 years expect significant or moderate impacts, with many citing reduced Australian investment, jobs and clinical trials. For biotech companies specifically (82% aged six years and older), the impact would be significant.
- Thirty-six (61%) said the proposed CGT changes would negatively impact them.
AusBiotech CEO Rebekah Cassidy said the survey results are yet more evidence that the proposed changes will do harm and must be reversed to ensure the sector is afforded certainty and confidence.
“The results send a clear message – companies already know they will be worse off under these changes, and if implemented as proposed, many will choose to leave,” Ms Cassidy said.
“The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector.
“The impacts are already being felt by the sector, with the changes being discussed within boardrooms, investment committees and development teams. Decisions about where clinical programs are located, where investment is deployed and where companies establish long-term operations are being influenced by perceptions of Australia's future competitiveness.
“The consequences are real and profound – lifesaving technologies could be shelved, promising clinical trials cancelled, companies closing, investors fleeing and some of our best talent leaving Australia.
“The proposals are at odds with existing Government policy which is confusing for the sector. For example, ‘Biotechnology’ is one of the Australian Government's seven Critical Technologies in the National Interest and a priority sector for the National Reconstruction Fund, while ‘Health and Medical’ is the first pillar of the Ambitious Australia: Strategic Examination of R&D report.
“Biotech is a major economic success story, supporting more than 350,000 jobs across almost 3,000 organisations. It makes no sense to jeopardise a sector which contributes so substantially to our economy and prosperity.
“We have been working with the sector on options to help Government to urgently fix the unintended outcomes of these poorly conceived proposed policy settings and get them right so that the sector can continue to grow, thrive and save lives. We just need Government to urgently meet us at the table.”
ENDS
Media: William Sparling [email protected] 0416 628 276
About AusBiotech
AusBiotech is Australia's leading national and global advocate for life sciences, working to help its more than 3500 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.